Loading...
•
Dec 31, 2023
Optinose Q4 2023 Earnings Report
Reported fourth quarter and full year 2023 financial results and recent operational highlights.
Key Takeaways
Optinose reported Q4 2023 XHANCE net revenue of $19.9 million and a net loss of $10.0 million, or $0.09 per share. The company is preparing for the potential launch of XHANCE for chronic sinusitis, pending FDA approval.
XHANCE net revenue for Q4 2023 was $19.9 million, a 5% decrease compared to Q4 2022.
The net loss for Q4 2023 was $10.0 million, or $0.09 per share.
Cash and cash equivalents totaled $73.7 million as of December 31, 2023.
The FDA has accepted the sNDA for XHANCE for chronic sinusitis with a PDUFA goal date of March 16, 2024.
Optinose
Optinose
Forward Guidance
The company expects XHANCE net revenues for the first quarter 2024 will be approximately $13.0 million and XHANCE average net revenue per prescription will be approximately $220 for full year 2024.